COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination

Area of Science:

• Oncology
• Infectious Diseases
• Public Health

Background:

• Cancer patients exhibit elevated risks for severe outcomes and mortality from SARS-CoV-2 (COVID-19).
• Existing research lacks detailed understanding of how cancer site, treatment, and vaccination status influence these risks.

Purpose of the Study:

• To investigate the association between cancer status, specific cancer types, treatments, and vaccination status with COVID-19 outcomes.
• To identify patient groups with heightened vulnerability to severe COVID-19.

Main Methods:

• Retrospective cohort study of 260,757 individuals tested for COVID-19.
• Analysis of electronic health records from an academic medical center (March 2020 - August 2022).
• Firth-corrected logistic regression used to assess associations with COVID-19 hospitalization, ICU admission, mortality, and severe outcomes.

Main Results:

• Cancer diagnosis significantly correlated with increased rates of severe COVID-19, hospitalization, and mortality, particularly within 3 years of diagnosis.
• Chemotherapy, colorectal cancer, hematologic malignancies, kidney cancer, and lung cancer were linked to worse COVID-19 outcomes.
• Vaccination demonstrated a significant protective effect, reducing severe COVID-19 outcomes irrespective of cancer status.

Conclusions:

• Individuals with colorectal cancer, hematologic malignancies, kidney cancer, lung cancer, or undergoing chemotherapy require heightened vigilance for severe COVID-19, even post-vaccination.
• Specific cancer types and treatments necessitate additional COVID-19 precautions.
• Vaccination provides significant benefits for both cancer patients and those without cancer.